What Happens If You Take Too Much Wegovy? Understanding Semaglutide Overdose Risks

Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

If you think you have taken too much semaglutide, contact your prescriber or the Poison Help line at 1-800-222-1222 — that is the instruction in the label itself, not a hedge. The Wegovy prescribing information states that overdoses have been reported with other GLP-1 receptor agonists, with effects including severe nausea, severe vomiting and severe hypoglycemia, and that appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms. It also notes that a prolonged period of observation and treatment may be necessary, taking into account semaglutide’s half-life of approximately one week.

What the Label Says About Overdose

Section 10 of the Wegovy label is brief and specific. Overdoses have been reported with other GLP-1 receptor agonists, and the effects reported have included severe nausea, severe vomiting and severe hypoglycemia. Management is supportive and guided by the patient’s clinical signs and symptoms.

The label directs consideration of contacting the Poison Help line at 1-800-222-1222 or a medical toxicologist for additional overdose management recommendations. The Ozempic label carries materially the same instruction.

The one detail that distinguishes semaglutide from most medications is duration. Because the elimination half-life is approximately one week, the labels specifically note that a prolonged period of observation and treatment may be necessary. There is no rapid clearance and no reversal agent.

Why Duration Is the Defining Feature

With a drug cleared over hours, an excessive dose produces a short, sharp problem. With semaglutide, exposure declines slowly. Steady-state exposure is reached after 4 to 5 weeks of once-weekly administration, and the same kinetics that make weekly dosing possible make an excessive exposure persist.

The label reflects this elsewhere too. It directs discontinuation in women at least two months before a planned pregnancy because of the long washout period. That instruction and the overdose observation instruction come from the same pharmacology.

The Downstream Risks That Follow Severe Gastrointestinal Effects

Severe vomiting and diarrhoea are not only unpleasant; they are the route to the complication the labels warn about most. The Wegovy label carries a warning on acute kidney injury due to volume depletion, noting reported cases of acute kidney injury and worsening of chronic renal failure, sometimes requiring haemodialysis, in patients treated with GLP-1 receptor agonists.

Those events occurred predominantly in patients who had experienced nausea, vomiting or diarrhoea leading to volume depletion. The label directs monitoring of renal function in patients reporting severe adverse gastrointestinal reactions.

Hypoglycemia is the other labeled concern, and the risk is concentrated in people also taking insulin or an insulin secretagogue such as a sulfonylurea. The label states that patients with diabetes taking Wegovy in combination with those agents may have an increased risk of hypoglycemia, including severe hypoglycemia.

Why Compounded Preparations Raise the Stakes

The FDA has received multiple reports of adverse events, some requiring hospitalisation, that may be related to dosing errors associated with compounded injectable semaglutide products. Those errors resulted from patients measuring and self-administering incorrect doses, and in some cases from health care professionals miscalculating doses.

The mechanism is structural. An approved pen or single-dose syringe delivers a fixed labeled amount. A preparation supplied in a vial requires someone to measure, and measurement introduces the possibility of error — including unit confusion between milligrams, milliliters and syringe units.

The agency has also flagged adverse event reports that may relate to compounded products being prescribed in doses beyond what is in the FDA-approved labeling, and has advised patients to talk with their health care provider or compounder about how to measure and administer the intended dose.

What Not to Do

Do not attempt to correct an excessive dose by skipping, delaying or otherwise adjusting subsequent doses on your own reasoning. Those decisions belong to the prescriber who knows your regimen and to the labeling for the specific product you were dispensed.

Do not treat the absence of immediate symptoms as reassurance. Maximum concentration is reached 1 to 3 days after a dose, so the peak effect of an excessive dose is not immediate. That is precisely why the labels contemplate a prolonged period of observation.

When to Seek Care Without Waiting

The labels identify the presentations that warrant urgent attention regardless of dose: persistent severe abdominal pain, sometimes radiating to the back and sometimes with vomiting, which raises the question of acute pancreatitis; symptoms of severe hypoglycemia; symptoms of gallbladder disease; and signs of dehydration or reduced urine output.

The Wegovy label also carries a warning about pulmonary aspiration during general anesthesia or deep sedation, and instructs patients to inform health care providers of any planned surgeries or procedures. That is worth remembering independently of any dosing question.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What does the label say to do after an overdose?

The Wegovy label states that appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms, and directs consideration of contacting the Poison Help line at 1-800-222-1222 or a medical toxicologist for additional overdose management recommendations. It notes that a prolonged period of observation and treatment may be necessary given the roughly one-week half-life.

What symptoms have been reported with GLP-1 overdose?

The label states that overdoses have been reported with other GLP-1 receptor agonists and that effects have included severe nausea, severe vomiting and severe hypoglycemia. Severe gastrointestinal reactions also open the route to the labeled warning on acute kidney injury due to volume depletion, which has included cases requiring haemodialysis in patients treated with this drug class.

Is there an antidote or a way to clear semaglutide quickly?

No. Management described in the labeling is supportive and symptom-guided. Because the elimination half-life is approximately one week and steady-state exposure builds over 4 to 5 weeks of once-weekly administration, exposure declines slowly, which is why the labels specifically contemplate a prolonged period of observation and treatment rather than a short one.

Why are dosing errors more common with compounded products?

The FDA has reported multiple adverse events, some requiring hospitalisation, that may relate to dosing errors with compounded injectable semaglutide, arising from patients measuring and self-administering incorrect doses and from professionals miscalculating doses. Approved pens and single-dose syringes deliver a fixed labeled amount, whereas a vial requires measurement, which introduces unit-conversion error.

Should I change my next dose if I took too much?

That decision belongs to your prescriber and to the labeling for the specific product you were dispensed, not to a general article. Contact your prescriber, and use the Poison Help line at 1-800-222-1222 for immediate guidance. Seek urgent care for persistent severe abdominal pain, signs of severe hypoglycemia, or signs of dehydration and reduced urine output.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.